Why Myriad Genetics, Inc.’s (MYGN) Stock Is Down 5.17%
As of Friday, October 30, Myriad Genetics, Inc.’s MYGN share price has dipped by 5.17%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile, a genomic profiling test; Prequel Prenatal Screen, a prenatal screening test to screen chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess risk of passing on recessive genetic condition to offspring; SneakPeek Early Gender DNA, a non-invasive blood test that predicts the fetus’s gender; FirstGene; and GeneSight Psychotropic Mental Health Medication, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company has a strategic alliance with SOPHiA GENETICS SA to advance new prostate cancer-specific genomic instability score technology for oncology approaches with AstraZeneca. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Commentary & Analysis
Why Myriad Genetics, Inc.’s (MYGN) Stock Is Up 35.39%
As of Tuesday, October 20, Myriad Genetics, Inc.’s MYGN share price has surged by 35.39%, which has investors questioning if this is right time to sell.Michael Rose
Why Myriad Genetics, Inc.’s (MYGN) Stock Is Up 37.17%
As of Tuesday, October 20, Myriad Genetics, Inc.’s MYGN share price has surged by 37.17%, which has investors questioning if this is right time to sell.Jenna Brashear
3 Undervalued Biotechnology Stocks for Friday, October 16
Discover the top 3 undervalued Biotechnology stocks for Friday, October 16 based on AAII’s Stock Grades.Jenna Brashear
Why Myriad Genetics, Inc.’s (MYGN) Stock Is Up 5.18%
As of Thursday, October 15, Myriad Genetics, Inc.’s MYGN share price has surged by 5.18%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | MYGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $607.4 | $226.9 | 40% |
|
| Shares Out (Mil) | 94.8 | 53.4 | 61% |
|
| Institutional Ownership | 95.2% | 92.9% | 67% |
|
| Float (Mil) | 79.3 | 40.7 | 56% |
|
| Beta | 1.64 | 0.95 | 85% |
|
| Avg Daily Volume (000s) | 4,606 | 469 | 91% |
|
| Price Change (52-week) |
(19.7%) | 46.6% | 36% |
|
| Growth | MYGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.2% | 12.8% | 51% |
|
| Net Income (5yr) | (47.1%) | (10.1%) | 8% |
|
| EPS (5yr) | (41.0%) | 15.8% | 5 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (1.3%) | (15.7%) | 63% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 9 | 9 | |
| Current EPS | ($0.200) | ($0.739) | ($0.589) | |
| Month Ago EPS | ($0.198) | ($0.739) | ($0.582) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.021) | ($0.253) | ($0.124) | |
| Year/Year Chg | (56.5%) | (81.3%) | (88.9%) | |
| Financials | MYGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $807 | $37 | 47% |
|
| Net Income (TTM) (Mil) | ($113) | ($44) | 10% |
|
| EPS (TTM) | ($1.202) | ($1.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | $8 | ($33) | 37% |
|
| Net Cash Flow (TTM) (Mil) | $33 | $2 | 66% |
|
| Long-Term Debt (Q1) (Mil) | $203 | $4 | 50% |
|
| Enterprise Value (Q1) (Mil) | $730 | $174 | 37% |
|
| Valuation | MYGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.00 | 2.17 | 54% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MYGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 68.8% | 65.6% | 80% |
|
| Net Margin | (14.0%) | (71.5%) | 19% |
|
| ROA | (17.1%) | (47.1%) | 21% |
|
| ROE | (32.5%) | (53.0%) | 19% |
|
| Liabilities to Assets | 52.4% | 29.6% | 45% |
|
| F-Score | 5 | 2 | 50% |
|
Myriad Genetics, Inc. did not pass any screens on 10/30/2026.
